NYSE:LLYPharmaceuticals
Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate
Eli Lilly (NYSE:LLY) received U.S. FDA approval for Foundayo, its first oral, once-daily GLP-1 weight loss pill for obesity and overweight patients with related conditions.
The company launched Foundayo commercially in the U.S. immediately after approval, making it available through LillyDirect and retail pharmacies.
Foundayo can be taken at any time without food or water restrictions and is being introduced with tailored pricing to broaden access.
Eli Lilly enters a new phase in obesity...